EX-10.22



 Exhibit 10.22 

* Certain confidential information contained in this document, 

marked by brackets, has been omitted and filed separately 

with the Securities and Exchange Commission pursuant to 

Rule 406 of the Securities Act of 1933, as amended. 

Extab Corporation 

(Registered number 4519307) 

Corporation Trust Centre, 1209 Orange Street, 

Wilmington, Delaware 19801 

Sopharma AD 
 16 Iliensko Shosse Str, 

1220 Sofia, Bulgaria 
 Attn: Chairman & CEO
Mr. Ognian Donev 
 Fax No. + 359 2 936 02 86 
 14
May 2015 
 Dear Sirs, 
 Variation of contract

 We refer to the Exclusive License Agreement between you and us dated 26 May 2009 (the “Agreement”), a copy of which is attached
to the Schedule to this latter agreement (the “Variation”). 
 For the consideration of £1, we wish to amend the Agreement as set out
in this Variation with effect from 14 May 2015 (the “Variation Date”). 
 Expressions defined in the Agreement and used In this
Variation have the meaning set out in the Agreement. 
 The Agreement is amended as follows: 

 

	1.	The definition “Sopharma territory” shall tie added: 

 “Sopharma
territory”: means Albania, Algeria, Armenia, Austria, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Georgia, Hungary, Kazakhstan, Kosovo, Kyrgyzstan, Latvia, Lithuania, Libya, Macedonia,
Moldova, Mongolia, Norway, Poland, Romania, Russia, Serbia, Slovakia, Sweden, Tajikistan, Tunisia, Turkey Turkmenistan, Ukraine, Uzbekistan and Vietnam, Iran and Afghanistan; 
  

	2.	The last line in the second paragraph in Section 2.1 shall be deleted and replaced in its entirety with: 


“exclusive supply agreement between the Parties dated 1 February 2010 (“Supply Agreement”). 

The remainder of Section 2.1 shall remain unchanged. 
  

	3.	Section 3 2 (a) shall be deleted and replaced in its entirety with: 

 “Extab shall pay
to Sopharma without set-off or counterclaim (save as otherwise permitted by this Agreement) a royalty of [...***...]% on Net Sales of Active Agent Product sold by Extab, its Affiliates or sublicensees
and their Affiliates in the Extab Territory throughout the Term.” 
  

*Confidential Treatment Requested 

  








 The remainder of Section 3.2 shall remain unchanged. 

 

	4.	Section 9.1 shall be deleted and replaced in its entirety with: 

 “Term, Unless
earlier terminated under this Section 9, the term of this Agreement shall begin on the Effective Date of this Agreement and shall remain in force for a period of 20 years from the Effective Date (“Term”) and may be extended by
mutual agreement of the Parties.” 
  

	5.	Section 9.3 (a) shall be deleted in its entirety and Section 9.2 (b) shall become Section 9.2. 

  

	6.	Section 9.4 shall be deleted and replaced in its entirety with: 

 “Each Party shall
have the right to terminate this Agreement upon written notice to the other Party; 
  

	 	a.	immediately upon such notice if an Insolvency Event of the other Party; or 

  

	 	b.	if the ether Party commits a material breach of this Agreement, and does not remedy such breach within 180 days of notice of such breach.” 


All other terms of the Agreement shall remain unchanged and in force. 

Please sign and return the enclosed copy of this letter to acknowledge your agreement to this Variation. 

Yours faithfully, 
  

	
	 /s/ Extab
Corporation                                       
             
 for and on behalf of EXTAB
CORPORATION


 We agree to the variation of the Agreement with effect from the Variation Date on the terms set out above. 

 

	
	 Signed /s/ Sopharma
AD                                    

for and on behalf SOPHARMA AD

	
	 Date
                
5/14/15                


  
 *Confidential Treatment Requested


  
 2 








 Schedule 

The Agreement 
  

*Confidential Treatment Requested 

  
 3